Benefit-Risk Assessment
What a definition is not
A definition is SPEQ’s plain-language decode of how a term is used in practice, cited to the documents that define it. It is a practitioner reference, not legal or regulatory advice, it does not replace the definition in the source, and where a regulator’s wording differs the regulator’s wording governs.
The structured evaluation of a medicinal product’s favorable effects against its unfavorable effects, conducted throughout development and the product lifecycle to support decisions on trial continuation, marketing authorization, and post-approval risk management. It weighs the severity, frequency, and reversibility of harms against the clinical benefit and the availability of alternative therapies.
Benefit-risk assessment is not a single calculation but a documented, reasoned judgment performed at multiple decision points: DMC review of interim data, evaluation of an aggregate safety report, the marketing application itself, and ongoing post-approval signal management.
The analysis weighs the severity, frequency, and reversibility of identified and potential risks against the magnitude, durability, and clinical relevance of the benefit, taking into account what alternative treatments — if any — are available to the population being studied.
Where the balance requires additional controls beyond the product’s use conditions, the assessment directly informs risk minimization measures such as a Risk Management Plan or REMS, rather than a simple approve/reject decision.
- —Performed continuously across the product lifecycle, not as a single one-time decision at approval.
- —Weighs severity, frequency, and reversibility of risks against the magnitude and durability of clinical benefit.
- —Directly informs risk minimization measures such as an RMP/REMS when the balance requires additional controls.
- —Documented in aggregate safety reports and in the benefit-risk sections of marketing applications.
ICH E2C(R2) Periodic Benefit-Risk Evaluation Report; FDA guidance, Benefit-Risk Assessment for New Drug and Biological Products
Frequently asked questions
What is Benefit-Risk Assessment?
The structured evaluation of a medicinal product’s favorable effects against its unfavorable effects, conducted throughout development and the product lifecycle to support decisions on trial continuation, marketing authorization, and post-approval risk management. It weighs the severity, frequency, and reversibility of harms against the clinical benefit and the availability of alternative therapies.
Which regulations cover Benefit-Risk Assessment?
ICH E2C(R2) Periodic Benefit-Risk Evaluation Report; FDA guidance, Benefit-Risk Assessment for New Drug and Biological Products